Yvonne Bombard1,2, Linda Rozmovits3, Anne Sorvari1,4, Corinne Daly1,4, June C Carroll5, Erin Kennedy2,6,7,8, Linda Rabeneck8,2,9, Nancy N Baxter1,2,4,6,8. 1. Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada. 2. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 3. Independent Qualitative Researcher, Toronto, Ontario, Canada. 4. Department of Surgery, St. Michael's Hospital, Toronto, Ontario, Canada. 5. Department of Family and Community Medicine, Sinai Health System, Toronto, Ontario, Canada. 6. Department of Surgery, University of Toronto, Toronto, Ontario, Canada. 7. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. 8. Cancer Care Ontario, Toronto, Ontario, Canada. 9. Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Abstract
PURPOSE: Population-based reflex testing of colorectal tumors can identify individuals with Lynch syndrome (LS), but there is debate regarding the type of patient discretion such a program warrants. We examined health-care providers' views and experiences to inform the design of a reflex-testing program and their perspectives regarding an opt-out option. METHODS: We interviewed providers managing LS or colorectal cancer patients, including surgeons, genetic counselors, oncologists, primary-care physicians, and gastroenterologists. Qualitative data were analyzed thematically using constant comparison techniques. RESULTS: Providers supported a reflex-testing program because of the current lack of coordinated immunohistochemistry (IHC) testing and underascertainment of LS patients as well as the opportunity to standardize the increasing use of genomic tests in practice. Most supported an opt-out after reflex testing because they felt that IHC is akin to other pathology tests, which are not optional. Some favored an opt-out before testing because of concern for patients experiencing distress, insurance discrimination, or a diagnostic odyssey that may be inconclusive. CONCLUSION: Providers support a reflex-testing program to improve the identification and management of suspected LS patients. However, how to support meaningful information provision to enable an opt-out without jeopardizing testing uptake and the anticipated public health benefits remains a policy challenge.Genet Med advance online publication 06 October 2016.
PURPOSE: Population-based reflex testing of colorectal tumors can identify individuals with Lynch syndrome (LS), but there is debate regarding the type of patient discretion such a program warrants. We examined health-care providers' views and experiences to inform the design of a reflex-testing program and their perspectives regarding an opt-out option. METHODS: We interviewed providers managing LS or colorectal cancer patients, including surgeons, genetic counselors, oncologists, primary-care physicians, and gastroenterologists. Qualitative data were analyzed thematically using constant comparison techniques. RESULTS: Providers supported a reflex-testing program because of the current lack of coordinated immunohistochemistry (IHC) testing and underascertainment of LS patients as well as the opportunity to standardize the increasing use of genomic tests in practice. Most supported an opt-out after reflex testing because they felt that IHC is akin to other pathology tests, which are not optional. Some favored an opt-out before testing because of concern for patients experiencing distress, insurance discrimination, or a diagnostic odyssey that may be inconclusive. CONCLUSION: Providers support a reflex-testing program to improve the identification and management of suspected LS patients. However, how to support meaningful information provision to enable an opt-out without jeopardizing testing uptake and the anticipated public health benefits remains a policy challenge.Genet Med advance online publication 06 October 2016.
Authors: Elizabeth Dicks; Daryl Pullman; Ken Kao; Andrée MacMillan; Gabrielle S Logan; Charlene Simmonds; Holly Etchegary Journal: Cancer Med Date: 2019-05-17 Impact factor: 4.452
Authors: Petra W C Lee; Angela C Bedard; Setareh Samimi; Vivienne K Beard; Quan Hong; James E J Bedard; Blake Gilks; David F Schaeffer; Robert Wolber; Janice S Kwon; Howard J Lim; Sophie Sun; Kasmintan A Schrader Journal: Cancer Med Date: 2020-07-23 Impact factor: 4.452
Authors: Richard Gallon; Peter Gawthorpe; Rachel L Phelps; Christine Hayes; Gillian M Borthwick; Mauro Santibanez-Koref; Michael S Jackson; John Burn Journal: Cancers (Basel) Date: 2021-01-22 Impact factor: 6.639
Authors: Salma Shickh; Leslie E Oldfield; Marc Clausen; Chloe Mighton; Agnes Sebastian; Alessia Calvo; Nancy N Baxter; Lesa Dawson; Lynette S Penney; William Foulkes; Mark Basik; Sophie Sun; Kasmintan A Schrader; Dean A Regier; Aly Karsan; Aaron Pollett; Trevor J Pugh; Raymond H Kim; Yvonne Bombard Journal: Oncologist Date: 2022-05-06 Impact factor: 5.837
Authors: George Kunnackal John; Vipin Das Villgran; Christine Caufield-Noll; Francis Giardiello Journal: Fam Cancer Date: 2020-09-11 Impact factor: 2.375